Everyone responds different to disease and treatment. We are working to understand how. Please visit our website to find out more and apply for our open positions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

BEREN AWARDED EXPEDITED ROADMAP FOR TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Beren Therapeutics | November 18, 2022

news image

Beren Therapeutics, P.B.C. a biotechnology company, announced that its novel lead asset, BRN-002, was awarded an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway for the reversal of atherosclerosis in patients with Homozygous Familial Hypercholesterolemia. The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases. HoFH is a rare gene...

Read More

PRESSURE BIOSCIENCES ANNOUNCES THE ACHIEVEMENT OF A CRITICAL MILESTONE IN REVOLUTIONARY NANOEMULSIFICATION TECHNOLOGY DEVELOPMENT

Pressure BioSciences, Inc. | October 07, 2020

news image

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the achievement of a critical milestone: the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology™ ("...

Read More

Cell and Gene Therapy

ELEVATEBIO ANNOUNCES ISSUANCE OF U.S. PATENT PROVIDING PROTECTION FOR RNA-GUIDED NUCLEASES IDENTIFIED THROUGH ITS LIFE EDIT GENE EDITING PLATFORM

ElevateBio | November 25, 2021

news image

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...

Read More

Medical, Industry Outlook

NONA BIOSCIENCES ANNOUNCES BUSINESS UPDATE OF COLLABORATION ON ANTIBODY DRUG CONJUGATE (ADC) WITH DUALITYBIO

PRNewswire | July 14, 2023

news image

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM) announced that, DualityBio, a collaborator of Nona Biosciences, and BeiGene entered into an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC program for patients with select solid tumors. This program wa...

Read More
news image

Industrial Impact

BEREN AWARDED EXPEDITED ROADMAP FOR TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Beren Therapeutics | November 18, 2022

Beren Therapeutics, P.B.C. a biotechnology company, announced that its novel lead asset, BRN-002, was awarded an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway for the reversal of atherosclerosis in patients with Homozygous Familial Hypercholesterolemia. The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases. HoFH is a rare gene...

Read More
news image

PRESSURE BIOSCIENCES ANNOUNCES THE ACHIEVEMENT OF A CRITICAL MILESTONE IN REVOLUTIONARY NANOEMULSIFICATION TECHNOLOGY DEVELOPMENT

Pressure BioSciences, Inc. | October 07, 2020

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the achievement of a critical milestone: the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology™ ("...

Read More
news image

Cell and Gene Therapy

ELEVATEBIO ANNOUNCES ISSUANCE OF U.S. PATENT PROVIDING PROTECTION FOR RNA-GUIDED NUCLEASES IDENTIFIED THROUGH ITS LIFE EDIT GENE EDITING PLATFORM

ElevateBio | November 25, 2021

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...

Read More
news image

Medical, Industry Outlook

NONA BIOSCIENCES ANNOUNCES BUSINESS UPDATE OF COLLABORATION ON ANTIBODY DRUG CONJUGATE (ADC) WITH DUALITYBIO

PRNewswire | July 14, 2023

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM) announced that, DualityBio, a collaborator of Nona Biosciences, and BeiGene entered into an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC program for patients with select solid tumors. This program wa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us